Do you want to read an article? Please log in or register.
Sex differences in 10-year cardiovascular risk of patients with type 2 diabetes mellitus and subclinical hypothyroidism: a cross-sectional study
Cardiovascular Risk and Diseases
Related content
COMMENTED
Cardiovascular Risk and Diseases
Risk differences and underlying factors of cardiovascular events and mortality in patients with type 2 diabetes versus type 1 diabetes: a longitudinal cohort study of Swedish nationwide register data
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol
Patsoukaki V, Lind L, Lampa E, Radhi S, Eeg-Olofsson K, Eliasson B, Eriksson JW
doi: 10.1016/S2213-8587(25)00165-2
Cardiovascular Risk and Diseases
Improving 10-year cardiovascular risk prediction in patients with type 2 diabetes with metabolomics
Cardiovasc Diabetol
Xie R, Seum T, Sha S, Trares K, Holleczek B, Brenner H, Schöttker B
doi: 10.1186/s12933-025-02581-3
Cardiovascular Risk and Diseases
Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies
Ann Intern Med
Saeed A, Mulukutla SR, Thoma F, Lemon L, Koczo A, Reis S, Marroquin O, Kip K
doi: 10.7326/ANNALS-24-00775
COMMENTED
Cardiovascular Risk and Diseases
Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol
Hauge JW, Borgeraas H, Birkeland KI, Johnson LK, Hertel JK, Hagen M, Gulseth HL, Lindberg M, Lorentzen J, Seip B, Kolotkin RL, Svanevik M, Valderhaug TG, Sandbu R, Hjelmesæth J, Hofsø D
doi: 10.1016/S2213-8587(24)00396-6
Cardiovascular Risk and Diseases
Low serum 1,5-anhydroglucitol is associated with increased risk of all-cause and cardiovascular mortality in type 2 diabetes: A real-world cohort study
Diabetes Obes Metab
Ni J, Chen L, Su H, Cai J, Wang C, Lu W, Wang Y, Lu J, Xia T, Zhou J
doi: 10.1111/dom.70214
Heart, Artery and Coronary Diseases
Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial
Am Heart J
Haff N, Horn DM, Bhatkhande G, Sung M, Colling C, Wood W, Robertson T, Gaposchkin D, Simmons L, Yang J, Yeh J, Crum KL, Hanken KE, Lauffenburger JC, Choudhry NK
doi: 10.1016/j.ahj.2025.02.007
Atrial FibrillationThrombosis and Stroke
Sex Differences and 2-Year Mortality in Patients With Atrial Fibrillation Diagnosed After Stroke and Known Atrial Fibrillation: A Register-Based Study in Sweden
J Am Heart Assoc
Al Khatib I, Viktorisson A, Abzhandadze T, Sunnerhagen KS
doi: 10.1161/JAHA.124.037608
Further Publications
Unsupervised Learning Analysis of Triglycerides, Inflammation, Cholesterol, and the Risks of Incident Cardiovascular Disease and Type 2 Diabetes in the Women's Health Study
J Am Heart Assoc
Duran EK, Cook NR, Aday AW, Buring JE, Ridker PM, Pradhan AD
doi: 10.1161/JAHA.123.039381
COMMENTED
Heart, Artery and Coronary Diseases
Heterogeneity of Cardiovascular Effects of Second-Line Glucose-Lowering Therapies in Adults With Type 2 Diabetes Across the Range of Moderate Baseline Cardiovascular Risk
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
J Am Heart Assoc
Deng Y, Polley EC, Herrin J, Swarna KS, Kent DM, Ross JS, Maron BA, Mickelson MM, McCoy RG
doi: 10.1161/JAHA.124.040217